FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033101917> ?p ?o ?g. }

• W3033101917 endingPage "28" @default.
• W3033101917 startingPage "22" @default.
• W3033101917 abstract "Apathy is a negative symptom of schizophrenia and is associated with poor real world functioning. Therefore, it is important to have validated psychometric instruments to assess this symptom. This is the first study to validate the Spanish adaptation of the self-rated version of the Apathy Assessment Scale (AES-S) in patients with schizophrenia. Naturalistic, cross-sectional, validation study in 104 patients with schizophrenia evaluated using the following scales: Clinical Global Impression-Severity (CGI-S), Personal and Social Performance (PSP), Clinical Assessment Interview for Negative Symptoms (CAINS), Self-report of Negative Symptoms (SNS), Motivation and Pleasure Scale-Self-Report (MAP-SR), Calgary Depression Scale for Schizophrenia (CDSS), and Apathy Evaluation Scale-self-rated version (AES-S). Reliability: Internal consistency (Cronbach's alpha) was 0.908. Convergent validity: The Pearson correlation coefficient between AES-S and CAINS-MAP total scores was −0.483 ( p < 0.001). For SNS, total and avolition subscale scores were −0.803 and −0.639 ( p < 0.001), respectively. With the MAP-SR, the correlation coefficient was −0.727 ( p < 0.001). Divergent validity: The Pearson correlation coefficient between AES-S and PSP total scores was 0.504 ( p < 0.001). Furthermore, with the CDSS, the correlation coefficient was −0.431 ( p < 0.001). Discriminant validity: The AES-S discriminated between different levels of illness severity according to CGI-S scores. Factor analysis: A three-component solution explained 57.32% of the variance. Pearson correlations between coefficients were 1–2 = 0.265, 1–3 = 0.464, and 2–3 = 0.060. The Spanish AES-S is a reliable and valid instrument for assessing apathy in Spanish patients with schizophrenia. It seems to be appropriate for use in everyday clinical practice as a means of monitoring apathy in these patients. La apatía es un síntoma negativo de la esquizofrenia, y está asociada a un mal funcionamiento del mundo real. Por tanto, es importante disponer de instrumentos psicométricos validados para valorar este síntoma. Este es el primer estudio que valida la adaptación al español de la versión auto-evaluada de la escala de evaluación de la apatía (AES-S) en pacientes esquizofrénicos. Estudio naturalista, transversal y de validación realizado en 104 pacientes esquizofrénicos evaluados utilizando las escalas siguientes: Clinical Global Impression-Severity (CGI-S), Personal and Social Performance (PSP), Clinical Assessment Interview for Negative Symptoms (CAINS), Self-report of Negative Symptoms (SNS), Motivation and Pleasure Scale-Self-Report (MAP-SR), Calgary Depression Scale for Schizophrenia (CDSS) y Apathy Evaluation Scale-self-rated version (AES-S). Fiabilidad: La consistencia interna (alfa de Cronbach) fue de 0,908. Validez convergente: El coeficiente de correlación de Pearson entre las puntuaciones totales de AES-S y CAINS-MAP fue de −0,483 (p < 0,001). Para SNS, las puntaciones totales y de la subescala de abulia fueron de −0,803 y −0,639 (p < 0,001), respectivamente. En cuanto a la escala MAP-SR, el coeficiente de correlación fue de −0,727 (p < 0,001). Validez divergente: El coeficiente de correlación de Pearson entre las puntuaciones totales de AES-S y PSP fue de 0,504 (p < 0,001). Además, en la escala CDSS, el coeficiente de correlación fue de −0,431 (p < 0,001). Validez discriminante: La escala AES-S discriminó entre los diferentes niveles de gravedad de la enfermedad, conforme a las puntuaciones CGI-S. Análisis factorial: Una solución de tres componentes explicó el 57,32% de la varianza. Las correlaciones de Pearson entre los coeficientes fueron de 1-2 = 0,265, 1-3 = 0,464 y 2-3 = 0,060. La versión española de AES-S es un instrumento fiable y válido para valorar la apatía en los pacientes esquizofrénicos españoles, que parece adecuado para utilizar en la práctica clínica diaria, como medio de cribado de la apatía en dichos pacientes." @default.
• W3033101917 created "2020-06-12" @default.
• W3033101917 creator A5001772756 @default.
• W3033101917 creator A5019160068 @default.
• W3033101917 creator A5021850889 @default.
• W3033101917 creator A5022265004 @default.
• W3033101917 creator A5027378045 @default.
• W3033101917 creator A5043060628 @default.
• W3033101917 creator A5043277477 @default.
• W3033101917 creator A5049463544 @default.
• W3033101917 creator A5064815642 @default.
• W3033101917 creator A5070750738 @default.
• W3033101917 creator A5084393887 @default.
• W3033101917 creator A5088958243 @default.
• W3033101917 date "2022-01-01" @default.
• W3033101917 modified "2023-10-18" @default.
• W3033101917 title "Validation of a European Spanish adaptation of the Apathy Evaluation Scale-self-rated version (AES-S) in patients with schizophrenia" @default.
• W3033101917 cites W1507042971 @default.
• W3033101917 cites W1831393147 @default.
• W3033101917 cites W1975965574 @default.
• W3033101917 cites W1982921548 @default.
• W3033101917 cites W1989128259 @default.
• W3033101917 cites W2008883202 @default.
• W3033101917 cites W2009337370 @default.
• W3033101917 cites W2010202486 @default.
• W3033101917 cites W2019691789 @default.
• W3033101917 cites W2047073785 @default.
• W3033101917 cites W2048187664 @default.
• W3033101917 cites W2072383853 @default.
• W3033101917 cites W2075198487 @default.
• W3033101917 cites W2145232965 @default.
• W3033101917 cites W2150819537 @default.
• W3033101917 cites W2165608395 @default.
• W3033101917 cites W2165851345 @default.
• W3033101917 cites W2167486251 @default.
• W3033101917 cites W2333927324 @default.
• W3033101917 cites W2418892200 @default.
• W3033101917 cites W2502787724 @default.
• W3033101917 cites W2580975499 @default.
• W3033101917 cites W2799633082 @default.
• W3033101917 cites W2802931820 @default.
• W3033101917 cites W2806528420 @default.
• W3033101917 cites W2896817500 @default.
• W3033101917 cites W4247665917 @default.
• W3033101917 cites W4317926736 @default.
• W3033101917 doi "https://doi.org/10.1016/j.rpsm.2020.04.008" @default.
• W3033101917 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32507728" @default.
• W3033101917 hasPublicationYear "2022" @default.
• W3033101917 type Work @default.
• W3033101917 sameAs 3033101917 @default.
• W3033101917 citedByCount "2" @default.
• W3033101917 countsByYear W30331019172022 @default.
• W3033101917 crossrefType "journal-article" @default.
• W3033101917 hasAuthorship W3033101917A5001772756 @default.
• W3033101917 hasAuthorship W3033101917A5019160068 @default.
• W3033101917 hasAuthorship W3033101917A5021850889 @default.
• W3033101917 hasAuthorship W3033101917A5022265004 @default.
• W3033101917 hasAuthorship W3033101917A5027378045 @default.
• W3033101917 hasAuthorship W3033101917A5043060628 @default.
• W3033101917 hasAuthorship W3033101917A5043277477 @default.
• W3033101917 hasAuthorship W3033101917A5049463544 @default.
• W3033101917 hasAuthorship W3033101917A5064815642 @default.
• W3033101917 hasAuthorship W3033101917A5070750738 @default.
• W3033101917 hasAuthorship W3033101917A5084393887 @default.
• W3033101917 hasAuthorship W3033101917A5088958243 @default.
• W3033101917 hasBestOaLocation W30331019172 @default.
• W3033101917 hasConcept C105795698 @default.
• W3033101917 hasConcept C106906290 @default.
• W3033101917 hasConcept C118552586 @default.
• W3033101917 hasConcept C120107772 @default.
• W3033101917 hasConcept C121244757 @default.
• W3033101917 hasConcept C121332964 @default.
• W3033101917 hasConcept C142724271 @default.
• W3033101917 hasConcept C15744967 @default.
• W3033101917 hasConcept C169900460 @default.
• W3033101917 hasConcept C171606756 @default.
• W3033101917 hasConcept C204787440 @default.
• W3033101917 hasConcept C27081682 @default.
• W3033101917 hasConcept C2776000289 @default.
• W3033101917 hasConcept C2776412080 @default.
• W3033101917 hasConcept C2776509080 @default.
• W3033101917 hasConcept C2778755073 @default.
• W3033101917 hasConcept C3018868096 @default.
• W3033101917 hasConcept C33923547 @default.
• W3033101917 hasConcept C49453240 @default.
• W3033101917 hasConcept C55078378 @default.
• W3033101917 hasConcept C62520636 @default.
• W3033101917 hasConcept C70410870 @default.
• W3033101917 hasConcept C71924100 @default.
• W3033101917 hasConceptScore W3033101917C105795698 @default.
• W3033101917 hasConceptScore W3033101917C106906290 @default.
• W3033101917 hasConceptScore W3033101917C118552586 @default.
• W3033101917 hasConceptScore W3033101917C120107772 @default.
• W3033101917 hasConceptScore W3033101917C121244757 @default.
• W3033101917 hasConceptScore W3033101917C121332964 @default.
• W3033101917 hasConceptScore W3033101917C142724271 @default.
• W3033101917 hasConceptScore W3033101917C15744967 @default.
• W3033101917 hasConceptScore W3033101917C169900460 @default.

• next